Inhibition of chemokine receptor CCR2 and CCR5 expression contributes to simvastatin-induced attenuation of cardiac allograft vasculopathy

被引:27
|
作者
Yin, Rong
Zhu, Jiaquan
Shao, Hongtao
Cheng, Xiaofeng
Feng, Xiaomei
Li, Zhongdong
Jing, Hua
机构
[1] Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Cardiothorac Surg, Nanjing 210002, Peoples R China
[2] Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Anesthesiol, Nanjing 210002, Peoples R China
来源
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2007年 / 26卷 / 05期
关键词
D O I
10.1016/j.healun.2007.02.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Accumulating evidence reveals that statins possess pleiotropic properties beyond cholesterol reduction, which may contribute to the attenuation of cardiac allograft vasculopathy (CAV). Recent in vitro data suggest that statins could down-regulate chemokine receptors. This study was designed to test the hypothesis that simvastatin ameliorates CAV development via the inhibition of chemokine receptor expression in an inbred rat model of cardiac transplantation. Methods: Animals were divided into four groups: isograft; control (cyclosporine [CsA] + vehicle); low-dose simvastatin (LSIM; CsA + 5 mg/kg simvastatin); and high-dose simvastatin (HSIM; CsA + 10 mg/kg simvastatin). Donor hearts from Fisher 344 rats were transplanted heterotopically into Lewis rat recipients. CsA was administered at 1.5 mg/kg/day for 2 weeks post-operatively. In addition, recipients were treated daily with simvastatin or vehicle for 8 weeks. Donor hearts were harvested for histopathologic and immunohistochemical examination. Intragraft concentration of chemokines and chemokine receptor. expression were analyzed using enzyme-linked immunosorbent assay and quantitative real-time polymerase chain reaction, respectively. Results: Both low and high doses of simvastatin significantly decreased the CAV score; inhibited recruitment of T lymphocytes and macrophages; reduced levels of intragraft MCP-1 (monocyte chemoattractant protein-1), RANTES (regulated on activation, normal T-cell expressed and secreted) protein and IP-10 (interferon-inducible protein-10); and down-regulated expression of chemokine receptors CCR2 and CCR5. CXCR3 expression was not affected by simvastatin treatment. Conclusions: Our results demonstrate that simvastatin may attenuate CAV development, possibly through retarding intragraft. chemokine accumulation and chemokine receptor expression. J Heart Lung Transplant 2007;26:485-93. Copyright (C) 2007 by the International Society for Heart and Lung Transplantation.
引用
收藏
页码:485 / 493
页数:9
相关论文
共 50 条
  • [1] Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice
    Mack, M
    Cihak, J
    Simonis, C
    Luckow, B
    Proudfoot, AEI
    Plachy, J
    Brühl, H
    Frink, M
    Anders, HJ
    Vielhauer, V
    Pfirstinger, J
    Stangassinger, M
    Schlöndorff, D
    JOURNAL OF IMMUNOLOGY, 2001, 166 (07): : 4697 - 4704
  • [2] Targeting of chemokine receptors CCR2 and CCR5 prolongs murine cardiac allograft survival.
    Gao, W
    Faia, K
    King, JA
    Smiley, ST
    Hancock, WW
    TRANSPLANTATION, 2000, 69 (08) : S125 - S125
  • [3] CCR2 AND CCR5 CHEMOKINE RECEPTOR POLYMORPHISMS AND THEIR INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Schauren, Juliana
    Consiglio, Camila R.
    Monticielo, Odirlei A.
    Xavier, Ricardo M.
    Brenol, Joao C.
    Chies, Jose A.
    TISSUE ANTIGENS, 2013, 81 (05): : 320 - 320
  • [4] Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus
    Aguilar, F
    Núñez-Roldán, A
    Torres, B
    Wichmann, I
    Sánchez-Román, J
    González-Escribano, MF
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (08) : 1770 - 1774
  • [5] Impact of Chemokine Receptor CCR2 and CCR5 Gene Polymorphism on Allograft Outcome in North Indian Renal Transplant Recipients
    Singh, R.
    Kapoor, R.
    Srivastava, A.
    Mittal, R. D.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2009, 69 (01) : 51 - 56
  • [6] A dual CCR2/CCR5 chemokine antagonist, BMS-813160?
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (12) : 1919 - 1924
  • [7] Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction
    González, P
    Alvarez, R
    Batalla, A
    Reguero, JR
    Alvarez, V
    Astudillo, A
    Cubero, GI
    Cortina, A
    Coto, E
    GENES AND IMMUNITY, 2001, 2 (04) : 191 - 195
  • [8] Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes
    Connolly, Kelli A.
    Belt, Brian A.
    Figueroa, Nathania M.
    Murthy, Aditi
    Patel, Ankit
    Kim, Minsoo
    Lord, Edith M.
    Linehan, David C.
    Gerber, Scott A.
    ONCOTARGET, 2016, 7 (52) : 86522 - 86535
  • [9] Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5
    Dawson, John R. D.
    Kufareva, Irina
    BIOPHYSICAL JOURNAL, 2023, 122 (03) : 185A - 185A
  • [10] Genotypes of CCR2 and CCR5 chemokine receptors in human myasthenia gravis
    Zhao, XY
    Gharizadeh, B
    Hjelmström, P
    Pirskanen, R
    Nyrén, P
    Lefvert, AK
    Ghaderi, M
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2003, 12 (05) : 749 - 753